目的 觀察替格瑞洛對氯吡格雷抵抗經(jīng)皮冠狀動脈介入治療（PCI）術(shù)后抗血小板治療的臨床效果。方法 選取2016年6月1日—2016年12月1日廊坊市廣陽區(qū)管道局總醫(yī)院心血管內(nèi)科、急診科收治的PCI術(shù)后冠心病患者100例，按隨機(jī)數(shù)字表法分為觀察組與對照組。對照組（50例）采用常規(guī)藥物治療，觀察組（50例）加用替格瑞洛治療。比較兩組術(shù)后血小板聚集率及心腦血管事件發(fā)生率。結(jié)果 術(shù)前，兩組血小板聚集率比較無顯著差異，術(shù)后2 h、1 d、1周，兩組血小板聚集率均有所下降（P<0.05）；且觀察組血小板聚集率明顯優(yōu)于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。隨訪期間，觀察組心腦血管事件發(fā)生率為2.00%（1/50），明顯低于對照組的14.00%（7/50），差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 替格瑞洛用于氯吡格雷抵抗PCI術(shù)后抗血小板治療，療效確切，可明顯降低術(shù)后血小板的聚集率，降低患者心腦血管病的發(fā)生率，值得臨床推廣。

Objective To observe the clinical effect of clopidogrel on antiplatelet therapy after percutaneous coronary intervention (PCI). Methods In this paper, 100 patients with coronary heart disease were selected from June 1, 2016 to December 1, 2016 in the department of cardiology and emergency department of our hospital, and the random number table method was divided into observation group and control group. The control group (50 cases) were treated with conventional medicine and the observation group (50 cases) was treated with tigrarro. The rate of platelet aggregation and the incidence of cardioascular eents were compared in two groups. Results Preoperative, two groups of platelet aggregation rate was no significant difference, postoperative 2 h, 1 d, 1 w and platelet aggregation rate of observation group was obviously better than the control group (P<0.05), statistically significant difference; During the follow-up period, the incidence of cardioascular eents in the observation group was 2.00% (1/50), which was significantly lower than the control group of 14.00% (7/50), and the difference was statistically significant (P<0.05). Conclusion For Greg los for clopidogrel resistance PCI postoperative antiplatelet therapy, curative effect, can obviously reduce postoperative platelet aggregation rate, reduce the incidence of patients with cardio-cerebral vascular disease, worthy of clinical promotion and use.

廊坊市科學(xué)技術(shù)研究與發(fā)展計劃（2016013186）